People · Operator
Named in public records as an officer, director or promoter · active 2016–2024 · Biotechnology, Other Technology, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Noetik Inc. | — | Biotechnology | Series B | $48.0M | $275.5M | 2022 |
| nTopology Inc. | — | Other Technology | Series C | $44.5M | $1.3B | 2020 |
| Shennon Biotechnologies Inc. | — | Biotechnology | Series A | $7.3M | $80.1M | 2022 |
| Sequence Bioinformatics Inc. | — | Other | Seed | $2.9M | $24.5M | 2016 |
James Hardiman at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside James Hardiman on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Amy Schulman | 1 | 11 |
| Carl Bass | 1 | 8 |
| Avidan Ross | 1 | 6 |
| Hrach Simonian | 1 | 4 |
| CHRIS GARDNER | 1 | 3 |
| Joshua Fredberg | 1 | 2 |
| Gregory Schroy | 1 | 2 |
| Bradley Rothenberg | 1 | 1 |
| Andrew Furey | 1 | 1 |
| Jacob Rinaldi | 1 | 1 |
| Ronald Alfa | 1 | 1 |
| Tyler Wish | 1 | 1 |
| LI SUN | 1 | 1 |
| MARK DOBBIN | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.